ALMS Stock Catalyst: Alumis Inc. Announces Positive Topline Results for Phase 3 Trials of Envudeucitinib

Alumis Inc. (Nasdaq: ALMS) announced on January 06, 2026, positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The trials involved 1,700 patients and used a 2:1:1 randomization ratio.

65% of patients achieved PASI 90, more than 40% achieved PASI 100, 74% achieved PASI 75, and 59% achieved sPGA 0/1. These results were observed over a 24-week period and compared favorably to placebo.

Alumis Inc. has a free float of 59,871,000 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.